

Registration No.

200001007481 (510087-M)

CANCER RESEARCH MALAYSIA

(Incorporated in Malaysia as a company
limited by guarantee and not having a share capital)

STATUTORY FINANCIAL STATEMENTS

FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2019

Registration No.

200001007481 (510087-M)

CANCER RESEARCH MALAYSIA
(Incorporated in Malaysia as a company
limited by guarantee and not having a share capital)

TRUSTEES

Toh Puan Dato' Seri Hajjah Dr Aishah Ong
Lim Siew Lian
Tengku Datuk Seri Ahmad Shah Al-Haj ibni Almarhum Sultan Salahuddin Abdul Aziz Shah Al-Haj
Alan Hamzah Sendut
Tan Sri Dato' Dr Ir Gan Thian Leong
Dato' Leong Kwei Chun
Datuk Professor Dr. Looi Lai Meng
Abd. Hamid bin Ibrahim (Resigned on 1 May 2019)
Leela Barrock (Resigned on 5 May 2020)

SECRETARIES

Chua Siew Chuan
Chin Mun Yee

AUDITORS

PricewaterhouseCoopers PLT (LLP0014401-LCA & AF 1146)
Chartered Accountants

REGISTERED OFFICE

Level 7, Menara Milenium
Jalan Damanlela, Pusat Bandar Damansara
Damansara Height
50490 Kuala Lumpur
Wilayah Persekutuan

PRINCIPAL PLACE OF BUSINESS

2nd Floor, Outpatient Centre
Sime Darby Medical Centre Subang Jaya
47500 Subang Jaya
Selangor Darul Ehsan
Malaysia

Registration No.

200001007481 (510087-M)

CANCER RESEARCH MALAYSIA

(Incorporated in Malaysia as a company
limited by guarantee and not having a share capital)

CONTENTS	PAGE(S)
TRUSTEES' REPORT	1 - 3
INCOME AND EXPENDITURE STATEMENTS	4
STATEMENTS OF FINANCIAL POSITION	5
STATEMENTS OF CHANGES IN GENERAL FUNDS	6
STATEMENTS OF CASH FLOWS	7 - 8
NOTES TO THE FINANCIAL STATEMENTS	9 - 31
STATEMENT BY TRUSTEES	32
STATUTORY DECLARATION	32
INDEPENDENT AUDITORS' REPORT	33 - 36

Registration No.

200001007481 (510087-M)

CANCER RESEARCH MALAYSIA

(Incorporated in Malaysia as a company
limited by guarantee and not having a share capital)

TRUSTEES' REPORT

The Trustees hereby submit their report together with the audited financial statements of the Economic Entity and of the Foundation for the financial year ended 31 December 2019.

PRINCIPAL ACTIVITY

The principal activity of the Foundation is to receive and administer funds for cancer research purposes. There have been no significant changes in the nature of this activity during the financial year.

The Foundation's joint venture is principally involved in rendering of services and products based in cell biology and cell culture technology. On 7 October 2019, the process to strike-off the name of the Foundation's joint venture, AseaCyte Sdn. Bhd. from the Register of the Companies Commission of Malaysia under Section 550 of the Companies Act 2016 (the Act") has been duly dissolved under the Act.

The Foundation is incorporated in Malaysia as a company limited by guarantee and does not have a share capital.

FINANCIAL RESULTS

	<u>Economic Entity</u> RM	<u>Foundation</u> RM
Excess of expenditure over income for the financial year	<u>(854,354)</u>	<u>(854,354)</u>

RESERVES AND PROVISIONS

There were no material transfers to or from reserves and provisions during the financial year.

BOARD OF TRUSTEES

The members of the Board of Trustees in office during the financial year and from the end of the financial year to the date of the report are:

Toh Puan Dato' Seri Hajjah Dr Aishah Ong
Lim Siew Lian
Tengku Datuk Seri Ahmad Shah Al-Haj ibni
Almarhum Sultan Salahuddin Abdul Aziz Shah Al-Haj
Alan Hamzah Sendut
Tan Sri Dato' Dr Ir Gan Thian Leong
Dato' Leong Kwei Chun
Datuk Professor Dr. Looi Lai Meng
Abd. Hamid bin Ibrahim
Leela Barrock

(Resigned on 1 May 2019)
(Resigned on 5 May 2020)

CANCER RESEARCH MALAYSIA

(Incorporated in Malaysia as a company
limited by guarantee and not having a share capital)

TRUSTEES' REPORT (CONTINUED)

TRUSTEES' BENEFITS

Since the end of the previous financial year, no Trustee has received or become entitled to receive a benefit by reason of a contract made by the Foundation or a related corporation with the Trustee or with a firm of which the Trustee is a member, or with a company in which the Trustee has a substantial financial interest.

During and at the end of the financial year, no arrangements subsisted to which the Foundation is a party, being arrangements with the object or objects of enabling the Trustees of the Foundation to acquire benefits by means of the acquisition of shares in, or debentures of, the Foundation or any other body corporate.

No trustee has received any remuneration during the financial year.

STATUTORY INFORMATION ON THE FINANCIAL STATEMENTS

Before the financial statements of the Economic Entity and of the Foundation were prepared, the Trustees took reasonable steps:

- (a) to ascertain that proper action had been taken in relation to the writing off of bad debts and the making of allowance for doubtful debts and satisfied themselves that all known bad debts had been written off and that adequate allowance had been made for doubtful debts; and
- (b) to ensure that any current assets, which were unlikely to realise in the ordinary course of business including the values of current assets as shown in the accounting records of the Economic Entity and of the Foundation, have been written down to an amount which the current assets might be expected so to realise.

At the date of this report, the Trustees are not aware of any circumstances:

- (a) which would render the amounts written off for bad debts or the amount of allowance for doubtful debts in the financial statements of the Economic Entity and of the Foundation inadequate to any substantial extent; or
- (b) which would render the values attributed to current assets in the financial statements of the Economic Entity and of the Foundation misleading; or
- (c) which have arisen which render adherence to the existing method of valuation of assets or liabilities of the Economic Entity and of the Foundation misleading or inappropriate.

No contingent or other liability has become enforceable or is likely to become enforceable within the period of twelve months after the end of the financial year which, in the opinion of the Trustees, will or may substantially affect the ability of the Economic Entity and of the Foundation to meet their obligations when they fall due.

CANCER RESEARCH MALAYSIA
(Incorporated in Malaysia as a company
limited by guarantee and not having a share capital)

TRUSTEES' REPORT (CONTINUED)

STATUTORY INFORMATION ON THE FINANCIAL STATEMENTS (CONTINUED)

At the date of this report, there does not exist:

- (a) any charge on the assets of the Economic Entity and of the Foundation which has arisen since the end of the financial year which secures the liability of any other person; or
- (b) any contingent liability of the Economic Entity and of the Foundation which has arisen since the end of the financial year.

At the date of this report, the Trustees are not aware of any circumstances not otherwise dealt with in this report or the financial statements which would render any amount stated in the financial statements misleading.

In the opinion of the Trustees:

- (a) the results of the Economic Entity's and of the Foundation's operations during the financial year were not substantially affected by any item, transaction or event of a material and unusual nature; and
- (b) there has not arisen in the interval between the end of the financial year and the date of this report any item, transaction or event of a material and unusual nature that is likely to affect substantially the results of the operations of the Economic Entity and of the Foundation for the financial year in which this report is made.

AUDITORS

The auditors, PricewaterhouseCoopers PLT (LLP0014401-LCA & AF 1146), have expressed their willingness to continue in office.

This report was approved by the Board of Trustees on 1 September 2020.

Signed on behalf of the Board of Trustees:



TOH PUAN DATO' SERI HAJJAH
DR AISHAH ONG

TRUSTEE



ALAN HAMZAH SENDUT

TRUSTEE

Kuala Lumpur

CANCER RESEARCH MALAYSIA(Incorporated in Malaysia as a company
limited by guarantee and not having a share capital)**INCOME AND EXPENDITURE STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2019**

		Economic Entity		Foundation	
	Note	2019 RM	2018 RM	2019 RM	2018 RM
INCOME					
Donations		6,643,530	10,120,275	6,643,530	10,120,275
Research grants		2,271,869	2,724,324	2,271,869	2,724,324
Other income		22,657	108,815	22,657	108,815
Interest income		414,088	338,827	414,088	338,827
		<u>9,352,144</u>	<u>13,292,241</u>	<u>9,352,144</u>	<u>13,292,241</u>
LESS: EXPENDITURE					
Staff costs	4	(5,002,852)	(5,101,712)	(5,002,852)	(5,101,712)
Research expenditure		(1,363,465)	(2,910,264)	(1,363,465)	(2,910,264)
Depreciation of property, plant and equipment	6	(769,938)	(1,050,034)	(769,938)	(1,050,034)
Depreciation of right-of-use asset	7	(173,155)	-	(173,155)	-
Write-off of property, plant and equipment		(50,158)	(7,019)	(50,158)	(7,019)
Training expenditure		(15,079)	(82,144)	(15,079)	(82,144)
Repairs and maintenance expenditure		(99,508)	(59,991)	(99,508)	(59,991)
Professional fees		(74,455)	(38,514)	(74,455)	(38,514)
Travelling expenses		(165,367)	(65,798)	(165,367)	(65,798)
Computer related expenses		(99,324)	(213,514)	(99,324)	(213,514)
Seminar/conference expenses		(130,127)	(272,496)	(130,127)	(272,496)
Insurance expenses		(36,352)	(23,771)	(36,352)	(23,771)
Marketing and fund raising expenses		(158,560)	(310,326)	(158,560)	(310,326)
Laboratory maintenance		(173,884)	(229,459)	(173,884)	(229,459)
Rental		(53,917)	(321,021)	(53,917)	(321,021)
Utilities		(115,155)	(116,986)	(115,155)	(116,986)
Purchased services		(1,298,392)	(233,167)	(1,298,392)	(233,167)
Dues and subscriptions		(15,188)	(44,215)	(15,188)	(44,215)
Interest expense on lease liability	11	(5,247)	-	(5,247)	-
Other expenses		(406,375)	(380,140)	(406,375)	(380,140)
		<u>(10,206,498)</u>	<u>(11,460,571)</u>	<u>(10,206,498)</u>	<u>(11,460,571)</u>
EXCESS OF (EXPENDITURE OVER INCOME)/INCOME OVER EXPENDITURE					
		(854,354)	1,831,670	(854,354)	1,831,670

CANCER RESEARCH MALAYSIA(Incorporated in Malaysia as a company
limited by guarantee and not having a share capital)**STATEMENTS OF FINANCIAL POSITION
AS AT 31 DECEMBER 2019**

	<u>Note</u>	<u>Economic Entity</u>		<u>Foundation</u>	
		<u>2019</u>	<u>2018</u>	<u>2019</u>	<u>2018</u>
		RM	RM	RM	RM
GENERAL FUNDS					
Balance at beginning of the financial year		16,319,772	14,488,102	16,319,772	14,488,102
Excess of (expenditure over income)/ Income over expenditure		(854,354)	1,831,670	(854,354)	1,831,670
Balance at end of the financial year		<u>15,465,418</u>	<u>16,319,772</u>	<u>15,465,418</u>	<u>16,319,772</u>
Represented by:					
NON-CURRENT ASSETS					
Property, plant and equipment	6	2,123,113	2,869,489	2,123,113	2,869,489
Right-of-use asset	7	46,318	-	46,318	-
Investment in joint venture	8	-	-	-	-
		<u>2,169,431</u>	<u>2,869,489</u>	<u>2,169,431</u>	<u>2,869,489</u>
CURRENT ASSETS					
Receivables	9	2,074,766	1,490,739	2,074,766	1,490,739
Deposits, cash and bank balances	10	11,826,768	13,303,966	11,826,768	13,303,966
		<u>13,901,534</u>	<u>14,794,705</u>	<u>13,901,534</u>	<u>14,794,705</u>
LESS: CURRENT LIABILITY					
Lease liability	11	44,720	-	44,720	-
Payables	12	560,827	1,032,189	560,827	1,032,189
Deferred income	13	-	312,233	-	312,233
		<u>605,547</u>	<u>1,344,422</u>	<u>605,547</u>	<u>1,344,422</u>
NET CURRENT ASSETS		<u>13,295,987</u>	<u>13,450,283</u>	<u>13,295,987</u>	<u>13,450,283</u>
NET ASSETS		<u>15,465,418</u>	<u>16,319,772</u>	<u>15,465,418</u>	<u>16,319,772</u>

Registration No.

200001007481 (510087-M)

CANCER RESEARCH MALAYSIA

(Incorporated in Malaysia as a company
limited by guarantee and not having a share capital)

**STATEMENTS OF CHANGES IN GENERAL FUNDS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2019**

	<u>Economic Entity</u>		<u>Foundation</u>	
	<u>2019</u>	<u>2018</u>	<u>2019</u>	<u>2018</u>
	RM	RM	RM	RM
As at 1 January	16,319,772	14,488,102	16,319,772	14,488,102
Excess of (expenditure over income)/ income over expenditure	(854,354)	1,831,670	(854,354)	1,831,670
As at 31 December	<u>15,465,418</u>	<u>16,319,772</u>	<u>15,465,418</u>	<u>16,319,772</u>

CANCER RESEARCH MALAYSIA

(Incorporated in Malaysia as a company
limited by guarantee and not having a share capital)

**STATEMENTS OF CASH FLOWS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2019**

		Economic Entity		Foundation	
	Note	2019 RM	2018 RM	2019 RM	2018 RM
OPERATING ACTIVITIES					
Excess of (expenditure over income)/ Income over expenditure		(854,354)	1,831,670	(854,354)	1,831,670
Adjustments for:					
Property, plant and equipment					
- depreciation		769,938	1,050,034	769,938	1,050,034
- write-off		50,158	7,019	50,158	7,019
Right-of-use asset					
- depreciation		173,155	-	173,155	-
Deferred income		(312,233)	(312,233)	(312,233)	(312,233)
Interest expense on lease liability		5,247	-	5,247	-
Interest income		(414,088)	(338,827)	(414,088)	(338,827)
		(582,177)	2,237,663	(582,177)	2,237,663
Changes in working capital:					
Receivables		(561,413)	970,716	(561,413)	970,716
Payables		(471,362)	(543,131)	(471,362)	(543,131)
Net cash flows (used in)/generated from operating activities		(1,614,952)	2,665,248	(1,614,952)	2,665,248
INVESTING ACTIVITIES					
Purchase of property, plant and equipment	6	(73,720)	(102,422)	(73,720)	(102,422)
Interest income		391,474	338,827	391,474	338,827
Increase/(decrease) in bank deposits maturing more than three months		1,975,707	(2,216,177)	1,975,707	(2,216,177)
Net cash flows generated from/(used in) investing activities		2,293,461	(1,979,772)	2,293,461	(1,979,772)

CANCER RESEARCH MALAYSIA(Incorporated in Malaysia as a company
limited by guarantee and not having a share capital)**STATEMENTS OF CASH FLOWS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2019 (CONTINUED)**

	<u>Note</u>	<u>Economic Entity</u>		<u>Foundation</u>	
		<u>2019</u>	<u>2018</u>	<u>2019</u>	<u>2018</u>
		<u>RM</u>	<u>RM</u>	<u>RM</u>	<u>RM</u>
FINANCING ACTIVITY					
Payment of lease liability		(180,000)	-	(180,000)	-
Net cash flow used in financing activity		(180,000)	-	(180,000)	-
NET INCREASE IN CASH AND CASH EQUIVALENTS					
		498,509	685,476	498,509	685,476
CASH AND CASH EQUIVALENTS AT BEGINNING OF THE FINANCIAL YEAR		2,598,259	1,912,783	2,598,259	1,912,783
CASH AND CASH EQUIVALENTS AT END OF THE FINANCIAL YEAR	10	3,096,768	2,598,259	3,096,768	2,598,259

Cash flows and non-cash changes in liability arising from financing activities are as follows:

	<u>As</u>		<u>Non-cash</u>	
	<u>1.1.2019</u>	<u>Cash flows</u>	<u>Changes</u>	<u>As</u>
	<u>RM</u>	<u>RM</u>	<u>Interest</u>	<u>31.12.2019</u>
			<u>expense</u>	<u>RM</u>
			<u>RM</u>	
Lease liability	219,473	(180,000)	5,247	44,720
	219,473	(180,000)	5,247	44,720

CANCER RESEARCH MALAYSIA
(Incorporated in Malaysia as a company
limited by guarantee and not having a share capital)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2019**

1 GENERAL INFORMATION

The Foundation is a company incorporated and domiciled in Malaysia, limited by guarantee and does not have a share capital. The registered office of the Foundation is located at Level 7, Menara Milenium, Jalan Damanlela, Pusat Bandar Damansara, Damansara Heights, 50490 Kuala Lumpur, Wilayah Persekutuan and the principal place of business of the Foundation is located at 2nd Floor, Outpatient Centre, Sime Darby Medical Centre Subang Jaya, 47500 Subang Jaya, Selangor Darul Ehsan.

The principal activity of the Foundation is to receive and administer funds for cancer research purposes. There have been no significant changes in the nature of this activity during the financial year.

The Foundation's joint venture is principally involved in rendering of services and products based in cell biology and cell culture technology. It remains dormant during the financial year.

The financial statements were authorised for issue by the Board of Trustees in accordance with a resolution dated 1 September 2020.

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

A BASIS OF PREPARATION

The financial statements of the Economic Entity and of the Foundation have been prepared in accordance with the provisions of the Malaysian Financial Reporting Standards ("MFRS"), International Financial Reporting Standards and the requirements of the Companies Act 2016 in Malaysia.

The financial statements of the Economic Entity are the financial statements of the Foundation in which equity method of accounting has been applied to account for its investment in the joint venture.

The financial statements have been prepared under the historical cost convention except as disclosed in this summary of significant accounting policies.

The preparation of financial statements in conformity with MFRS requires the use of certain critical accounting estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of income and expenses during the reported period. It also requires the Trustees to exercise their judgement in the process of applying the Economic Entity's and the Foundation's accounting policies. Although these estimates and judgement are based on the Trustees' best knowledge of current events and actions, actual results may differ.

The Trustees are of the view that there were no critical accounting estimates and assumptions which would have a material impact to the Economic Entity's and the Foundation's income and expenditure and financial position or accounting policies that require subjective judgement in the current financial year.

CANCER RESEARCH MALAYSIA

(Incorporated in Malaysia as a company
limited by guarantee and not having a share capital)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2019 (CONTINUED)**

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

A BASIS OF PREPARATION (CONTINUED)

- (a) Accounting pronouncements that are effective and have been adopted by the Economic Entity and the Foundation as at 1 January 2019:

- MFRS 16 "Leases"
- Amendments to MFRS 9 "Financial Instruments" - Prepayment Features with Negative Compensation
- Amendments to MFRS 119 "Employee Benefits" - Plan Amendment, Curtailment or Settlement

The Foundation has adopted MFRS 16 retrospectively with the cumulative effect of initially applying the new standard recognised on 1 January 2019. Comparatives for the 2018 financial year have not been restated. The impact of the change in accounting policy is disclosed in Note 14.

Other than adoption of MFRS 16, the adoption of other pronouncements did not have significant impact on the financial statements of the Foundation. The details of the adoption of MFRS 16 are disclosed in Note 14.

- (b) Accounting pronouncements that are not yet effective and have not been early adopted by the Economic Entity and the Foundation:

Effective for annual periods beginning on or after 1 January 2020 with earlier application permitted

Amendments to existing standards and other accounting pronouncements that are not expected to have any significant impact on the financial statements of the Economic Entity:

- The Conceptual Framework for Financial Reporting
- Amendments to MFRS 101 'Presentation of Financial Statements' and MFRS 108 'Accounting Policies, Changes in Accounting Estimates and Errors' - Definition of Material'

The Trustees are currently assessing the impact of the above pronouncements on the financial statements of the Economic Entity and of the Foundation.

CANCER RESEARCH MALAYSIA

(Incorporated in Malaysia as a company
limited by guarantee and not having a share capital)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2019 (CONTINUED)**

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

B DONATIONS AND RESEARCH GRANTS

Donations and research grants are recognised as income when the Economic Entity's and the Foundation's right to receive payment is established.

C OTHER INCOME

Interest income is recognised on a time proportion basis, taking into account the principal outstanding and the effective interest rate over the period to maturity, when it is determined that such income will accrue to the Economic Entity and the Foundation.

Income from advisory and consultancy service is recognised when the services are provided.

D PROPERTY, PLANT AND EQUIPMENT

Plant and equipment are stated at historical cost less accumulated depreciation and impairment losses. The cost of an item of plant and equipment initially recognised includes its purchase price, import duties, non-refundable purchase taxes and any cost that is directly attributable in bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management. Cost also includes borrowing costs that are directly attributable to the acquisition, construction or production of a qualifying asset.

Subsequent costs are included in the asset's carrying amount or recognised as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the Economic Entity and the Foundation and the cost of the item can be measured reliably. The carrying amount of the replaced part is de-recognised. All other repairs and maintenance are recognised as expenses in profit or loss during the period in which they are incurred.

Gains or losses on disposals are determined by comparing proceeds with carrying amount and are included in profit or loss.

Plant and equipment are depreciated on the straight line method to allocate the costs to their residual values over their estimated useful lives, summarised as follows:

<u>Property, plant and equipment</u>	<u>Estimated useful lives</u>
Laboratory equipment	10 years
Renovations	4 years
Computers	3 years
Office equipment	10 years

Residual values and useful lives of assets are reviewed, and adjusted if appropriate, at the end of each reporting period. At the end of the reporting period, the Economic Entity and the Foundation assesses whether there is any indication of impairment. If such indications exist, an analysis is performed to assess whether the carrying amount of the asset is fully recoverable. A write down is made if the carrying amount exceeds the recoverable amount. See accounting policy E on impairment of non-financial assets.

CANCER RESEARCH MALAYSIA

(Incorporated in Malaysia as a company
limited by guarantee and not having a share capital)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2019 (CONTINUED)**

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

E IMPAIRMENT OF NON-FINANCIAL ASSETS

Assets that are subject to amortisation are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. An impairment loss is recognised for the amount by which the carrying amount of the asset exceeds its recoverable amount. The recoverable amount is the higher of an asset's fair value less costs to sell and value-in-use. For the purposes of assessing impairment, assets are grouped at the lowest level for which there are separately identifiable cash flows (cash-generating units). Non-financial assets other than goodwill that suffered impairment are reviewed for possible reversal of the impairment at the end of each reporting date.

The impairment loss is charged to the income and expenditure statements and any subsequent increase in recoverable amount is recognised in the income and expenditure statements.

F GOVERNMENT GRANTS

Grants from the government are recognised at their fair values when there is a reasonable assurance that the grant will be received and the Economic Entity and the Foundation will comply with their attached conditions.

Government grants relating to costs are deferred and recognised in the income and expenditure statements over the period necessary to match them with the costs they are intended to compensate.

Government grants relating to the purchase of assets are included in liabilities as deferred income and are credited to the income and expenditure statements on a straight line basis over the expected useful lives of the related assets.

G CASH AND CASH EQUIVALENTS

For the purpose of the statement of cash flows, cash equivalents are held for the purpose of meeting short-term cash commitments rather than for investment or other purposes. Cash and cash equivalents comprise cash on hand, deposits held at call with financial institutions, other short term, highly liquid investments with original maturities of 3 months or less that are readily convertible to known amounts of cash and are subject to an insignificant risk of changes in value.

CANCER RESEARCH MALAYSIA

(Incorporated in Malaysia as a company
limited by guarantee and not having a share capital)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2019 (CONTINUED)**

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

H EMPLOYEE BENEFITS

(a) Short term benefits

Wages, salaries, bonuses and social security contributions are recognised as an expense in the period in which the associated services are rendered by employees of the Economic Entity and the Foundation.

(b) Defined contribution plans

The Economic Entity and the Foundation's contributions to defined contribution plans are charged to profit or loss in the period to which they relate. Prepaid contributions are recognised as an asset to the extent that a cash refund or a reduction in the future payments is available.

I FINANCIAL ASSETS

(i) Classification

The Economic Entity and the Foundation classifies its financial assets as those to be measured at amortised cost.

(ii) Recognition and initial measurement

Regular way purchases and sales of financial assets are recognised on trade-date, the date on which the Economic Entity and the Foundation commit to purchase or sell the asset. Financial assets are derecognised when the rights to receive cash flows from the financial assets have expired or have been transferred and the Economic Entity and the Foundation have transferred substantially all the risks and rewards of ownership.

(iii) Subsequent measurement

• **Debt instruments at amortised cost**

After initial recognition, financial assets that are held for collection of contractual cash flows where those cash flows represent solely payment of principal and interest are measured at amortised cost using the effective interest method. Any gain or loss arising on derecognition is recognised directly in profit or loss and presented in 'other operating income' or 'other operating expenses'.

CANCER RESEARCH MALAYSIA

(Incorporated in Malaysia as a company
limited by guarantee and not having a share capital)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2019 (CONTINUED)**

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

I FINANCIAL ASSETS (CONTINUED)

(iv) Impairment

The Economic entity and Foundation assess on a forward looking basis the expected credit loss ('ECL') associated with its debt instruments carried at amortised cost. The impairment methodology applied depends on whether there has been a significant increase in credit risk.

The financial instruments held by the Economic Entity and the Foundation that are subject to the ECL model are donations receivable and other receivables. While cash and bank balances are also subject to the impairment requirements of MFRS 9, the identified impairment loss was immaterial.

ECL represent a probability-weighted estimate of the difference between present value of cash flows according to contract and present value of cash flows the Economic Entity and the Foundation expect to receive, over the remaining life of the financial instrument.

The measurement of ECL reflects:

- an unbiased and probability-weighted amount that is determined by evaluating a range of possible outcomes;
- the time value of money; and
- reasonable and supportable information that is available without undue cost or effort at the reporting date about past events, current conditions and forecasts of future economic conditions.

General 3-stage approach for donation receivables and other receivables

At each reporting date, the Economic Entity and the Foundation measure ECL through loss allowance at an amount equal to 12 month ECL if credit risk on a financial instrument or a group of financial instruments has not increased significantly since initial recognition. For all other financial instruments, a loss allowance at an amount equal to lifetime ECL is required.

(v) Significant increase in credit risk

The Economic Entity and the Foundation consider the probability of default upon initial recognition of asset and whether there has been a significant increase in credit risk on an ongoing basis throughout each reporting period. To assess whether there is a significant increase in credit risk, the Economic Entity and the Foundation compare the risk of a default occurring on the asset as at the reporting date with the risk of default as at the date of initial recognition. It considers available reasonable and supportable forward-looking information.

CANCER RESEARCH MALAYSIA

(Incorporated in Malaysia as a company
limited by guarantee and not having a share capital)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2019 (CONTINUED)**

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

I FINANCIAL ASSETS (CONTINUED)

(vi) Definition of default and credit-impaired financial assets

The Economic Entity and Foundation define a financial instrument as default, which is fully aligned with the definition of credit-impaired, when it meets one or more of the following criteria:

- When the counterparty fails to make contractual payment when they fall due.
- it is becoming probable that the debtor will enter bankruptcy or other financial reorganise
- the debtor is insolvent

(vii) Write-off

Financial assets are written off when the Economic Entity and the Foundation have exhausted all practical recovery efforts and have concluded that there is no reasonable expectation of recovery. Indicator of no reasonable expectation of recovery include failure of a debtor to engage in a repayment plan with the Economic Entity and the Foundation. The Economic Entity and the Foundation may write-off financial assets that are still subject to enforcement activity.

(viii) De-recognition

Financial assets are derecognised when the rights to receive cash flows from the financial assets have expired or have been transferred and the Economic Entity and the Foundation have transferred substantially all the risks and rewards of ownership.

CANCER RESEARCH MALAYSIA
(Incorporated in Malaysia as a company
limited by guarantee and not having a share capital)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2019 (CONTINUED)

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

J FINANCIAL LIABILITIES

A financial liability is any liability that is a contractual obligation to deliver cash or another financial asset to another enterprise, or to exchange financial instruments in another enterprise under conditions that are potentially unfavourable.

Financial liabilities are recognised in the statements of financial position when, and only when, the Economic Entity and the Foundation become a party to the contractual provisions of the financial instrument.

The Economic Entity and the Foundation classify the financial liabilities as other financial liabilities. The classification depends on the nature of the liabilities and the purpose for which the financial liabilities were incurred. Management determines the classification at initial recognition.

Other financial liabilities

Other financial liabilities comprise 'payables' (Note 12).

When other financial liabilities are recognised initially, they are measured at fair value plus directly attributable transaction costs.

Subsequent to the initial recognition, other financial liabilities are measured at amortised cost using the effective interest method. Gains and losses are recognised in the income and expenditure statements when the other financial liabilities are derecognised, and through the amortisation process.

Financial liabilities are derecognised when the obligation specified in the contract is discharged, cancelled or expired.

Financial liabilities are classified as current liabilities for those having maturity dates of less than twelve months after the reporting date, otherwise, the balance is classified as non-current.

K OFFSETTING FINANCIAL INSTRUMENTS

Financial assets and liabilities are offset and the net amount is presented in the statements of financial position when there is a legally enforceable right to offset the recognised amounts and there is an intention to settle on a net basis, or realise the asset and settle the liability simultaneously.

CANCER RESEARCH MALAYSIA

(Incorporated in Malaysia as a company
limited by guarantee and not having a share capital)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2019 (CONTINUED)**

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

L LEASES

The Foundation as a lessee

Accounting policies applied from 1 January 2019

From 1 January 2019, leases are recognised as right-of-use ("ROU") assets and a corresponding liability at the date on which the leased asset is available for use by the Foundation (i.e. the commencement date).

Contracts may contain both lease and non-lease components. The Foundation allocates the consideration in the contract to the lease and non-lease components based on their relative stand-alone prices. However, for leases of properties for which the Foundation is a lessee, it has elected the practical expedient provided in MFRS 16 not to separate lease and non-lease components. Both components are accounted for as a single lease component and payments for both components are included in the measurement of lease liability.

(a) Lease term

In determining the lease term, the Foundation considers all facts and circumstances that create an economic incentive to exercise an extension option, or not to exercise a termination option. Extension options (or periods after termination options) are only included in the lease term if the lease is reasonably certain to be extended (or not to be terminated).

The Foundation reassesses the lease term upon the occurrence of a significant event or change in circumstances that is within the control of the Foundation and affects whether the Foundation is reasonably certain to exercise an option not previously included in the determination of lease term, or not to exercise an option previously included in the determination of lease term. A revision in lease term results in remeasurement of the lease liabilities (refer to (d) below).

(b) ROU assets

ROU assets are initially measured at cost comprising the following:

- The amount of the initial measurement of lease liability;
- Any lease payments made at or before the commencement date less any lease incentive received;
- Any initial direct costs; and
- Decommissioning or restoration costs.

The ROU asset is depreciated over the shorter of the right-of-use asset's useful life and the lease term on a straight-line basis, as follows:

ROU asset

Lease term

Premise

3 years

CANCER RESEARCH MALAYSIA
(Incorporated in Malaysia as a company
limited by guarantee and not having a share capital)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2019 (CONTINUED)

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

L LEASES (CONTINUED)

The Foundation as a lessee (continued)

Accounting policies applied from 1 January 2019 (continued)

(b) ROU assets (continued)

The ROU assets are adjusted for any remeasurement of the lease liability.

At each statement of financial position date, the Foundation assess whether there is any indication of impairment. If such an indication exists, an analysis is performed to assess whether the carrying amount of the asset is fully recoverable. An asset's carrying amount is written down immediately to its recoverable amount if the asset's carrying amount is greater than its estimated recoverable amount.

(c) Lease liabilities

Lease liabilities are initially measured at the present value of the lease payments that are not paid at that date. The lease payments include the following:

- Fixed payments (including in-substance fixed payments), less any lease incentive receivable;
- Variable lease payments that are based on an index or a rate, initially measured using the index or rate as at the commencement date;
- Amounts expected to be payable by the Foundation under residual value guarantees;
- The exercise price of a purchase and extension options if the Foundation is reasonably certain to exercise that option; and
- Payments of penalties for terminating the lease, if the lease term reflects the Foundation exercising that option.

Lease payments are discounted using the interest rate implicit in the lease. If that rate cannot be readily determined, which is generally the case for leases in the Foundation, the lessee's incremental borrowing is used. This is the rate that the individual lessee would have to pay to borrow the funds necessary to obtain an asset of similar value to the ROU in a similar economic environment with similar term, security and conditions.

Lease payments are allocated between principal and finance cost. The finance cost is charged to profit or loss over the lease period so as to produce a constant periodic rate of interest on the remaining balance of the liability for each period. Variable lease payments that depend on sales are recognised in profit or loss in the period in which the condition that triggers those payments occurs.

The Foundation presents the lease liabilities as a separate line item in the statement of financial position. Interest expense on the lease liability is presented within the finance cost in the statement of profit or loss.

CANCER RESEARCH MALAYSIA
(Incorporated in Malaysia as a company
limited by guarantee and not having a share capital)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2019 (CONTINUED)

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

L LEASES (CONTINUED)

The Foundation as a lessee (continued)

Accounting policies applied from 1 January 2019 (continued)

(d) Reassessment of lease liabilities

The Foundation is also exposed to potential future increases in variable lease payments that depend on an index or rate, which are not included in the lease liability until they take effect. When adjustments to lease payments based on an index or rate take effect, the lease liability is remeasured and adjusted against the ROU assets.

(e) Short-term leases and leases of low-value assets

Short-term leases are leases with a lease term of 12 months or less. Low-value assets comprise IT equipment and small items of office furniture. Payments associated with short-term leases of equipment and vehicles and all leases of low-value assets are recognised on a straight-line bases as an expense in profit or loss.

Accounting policies applied until 31 December 2018

Finance leases

Until 31 December 2018, leases of property, plant and equipment where the Foundation has substantially transferred all the risks and rewards of ownership are classified as finance leases. Finance leases are capitalised at the lease's commencement at the lower of the fair value of the leased property and the present value of the minimum lease payments. The corresponding rental obligations, net of finance charges, are included in other short-term and long-term payables.

Each lease payment is allocated between the liability and finance charges so as to achieve a constant rate of interest on the remaining balance of the liability.

The finance cost is charged to profit or loss over the lease period so as to produce a constant periodic rate of interest on the remaining balance of the liability for each period. The property, plant and equipment acquired under finance leases is depreciated over the shorter of the useful life of the asset and the lease term if there is no reasonable certainty that the Foundation will obtain ownership at the end of the lease term.

Initial direct costs incurred by the Foundation in negotiating and arranging finance leases are added to the carrying amount of the leased assets and recognised as an expense in profit or loss over the lease term on the same basis as the lease expense.

Operating lease

Leases in which a significant (substantially all) portion of the risks and rewards of ownership are not transferred to the Foundation as lessee are classified as operating leases. Payments made under operating leases (net of any incentives received from the lessor) are charged to profit or loss on a straight-line basis over the period of the lease.

CANCER RESEARCH MALAYSIA

(Incorporated in Malaysia as a company
limited by guarantee and not having a share capital)

NOTES TO THE FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2019 (CONTINUED)

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

M JOINT ARRANGEMENTS

A joint arrangement is an arrangement of which there is contractually agreed sharing of control by the Foundation with one or more parties, where decisions about the relevant activities relating to the joint arrangement require unanimous consent of the parties sharing control. The classification of a joint arrangement as a joint operation or a joint venture depends upon the rights and obligations of the parties to the arrangement. A joint venture is a joint arrangement whereby the joint venturers have rights to the net assets of the arrangement. A joint operation is a joint arrangement whereby the joint operators have rights to the assets and obligations for the liabilities, relating to the arrangement.

The Foundation's interest in a joint venture is accounted for in the financial statements by the equity method of accounting. Under the equity method of accounting, interests in joint ventures are initially recognised at cost and adjusted thereafter to recognise the Foundation's share of the post-acquisition profits or losses and movements in other comprehensive income. When the Foundation's share of losses in a joint venture equals or exceeds its interests in the joint ventures (which includes any long-term interests that, in substance, form part of the Foundation's net investment in the joint ventures), the Foundation does not recognise further losses, unless it has incurred obligations or made payments on behalf of the joint ventures.

Unrealised gains on transactions between the Foundation and its joint venture are eliminated to the extent of the Foundation's interest in the joint venture. Unrealised losses are also eliminated unless the transaction provides evidence of an impairment of the asset transferred. Accounting policies of the joint venture have been changed where necessary to ensure consistency with the policies adopted by the Foundation.

In the Foundation's separate financial statements, investment in joint venture is carried at cost less accumulated impairment losses. On disposal of investment in joint venture, the difference between the disposal proceeds and the carrying amounts of the investments are recognised in income and expenditure statements.

N CONTINGENT ASSETS AND CONTINGENT LIABILITIES

The Economic Entity and the Foundation do not recognise a contingent asset and liability but discloses its existence in the financial statements. A contingent liability is a possible obligation that arises from past events whose existence will be confirmed by the occurrence or non-occurrence of one or more uncertain future events beyond the control of the Economic Entity and the Foundation or a present obligation that is not recognised because it is not probable that an outflow of resources will be required to settle the obligation. A contingent liability also arises in the extremely rare circumstance where there is a liability that cannot be recognised because it cannot be measured reliably. However, contingent liabilities do not include financial guarantee contracts.

A contingent asset is a possible asset that arises from past events whose existence will be confirmed by the occurrence or non-occurrence of one or more uncertain future events beyond the control of the Economic Entity and the Foundation. The Economic Entity and the Foundation do not recognise contingent assets but discloses its existence where inflows or economic benefits are probable, but not virtually certain.

CANCER RESEARCH MALAYSIA

(Incorporated in Malaysia as a company
limited by guarantee and not having a share capital)

NOTES TO THE FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2019 (CONTINUED)

3 FINANCIAL RISK MANAGEMENT OBJECTIVES AND POLICIES

The Economic Entity and Foundation are exposed to financial risks arising from their operations and the use of financial instruments. The key financial risks include credit risk and liquidity risk.

The following sections provide details regarding the Economic Entity's and Foundation's exposure to the above-mentioned financial risks and the objectives, policies and processes for the management of these risks.

(a) Credit risk

Credit risk is the risk of loss that may arise on outstanding financial instruments should a counterparty default on its obligations. At the reporting date, the Economic Entity's and Foundation's maximum exposure to credit risk is represented by the carrying amount of each class of financial assets recognised in the statements of financial position.

Measurement of Expected Credit Loss ("ECL")

General 3-stage approach for donation receivables and other receivables

Donations receivables and other receivables are considered to have low credit risk, and thus the impairment provision during the period was limited to 12 months expected credit loss. They are considered to be low credit risk as they have a low risk of default and the counterparties have strong capacity to meet their contractual cash flow obligations in the near term.

Cash and cash equivalents and deposits of the Foundation are placed with credit worthy financial institutions and the risks arising therefrom are minimised in view of the financial strength of these financial institutions.

(b) Liquidity risk

Liquidity risk is the risk that the Economic Entity and Foundation will encounter difficulty in meeting financial obligations due to shortage of funds. The Economic Entity's and Foundation's exposure to liquidity risk arises primarily from mismatch of the maturity of the financial assets and liabilities.

The Economic Entity and the Foundation adopt prudent liquidity risk management by maintaining sufficient cash resources and having available funding through donors. The Economic Entity's and the Foundation's operations are financed mainly through donations and research grants received.

As at the statement of financial position date, the remaining contractual maturity periods for the Foundation's financial liabilities are within a period of less than 1 year.

CANCER RESEARCH MALAYSIA(Incorporated in Malaysia as a company
limited by guarantee and not having a share capital)**NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2019 (CONTINUED)****4 STAFF COSTS**

	<u>Economic Entity and Foundation</u>	
	<u>2019</u>	<u>2018</u>
	RM	RM
Salaries, wages and overtime	4,256,607	4,492,919
Defined contribution plan	593,975	529,792
Other employee benefits	152,270	79,001
	<u>5,002,852</u>	<u>5,101,712</u>

5 TAXATION

No provision has been made for taxation as the Foundation is a charitable institution which is exempted from tax by virtue of Section 127 (1) of the Income Tax Act, 1967 (Paragraph 13(1)(a) of Schedule 6).

6 PROPERTY, PLANT AND EQUIPMENTEconomic Entity and Foundation

	<u>Laboratory equipment</u>	<u>Renovations</u>	<u>Computers</u>	<u>Office equipment</u>	<u>Total</u>
	RM	RM	RM	RM	RM
<u>2019</u>					
<u>Cost</u>					
At 1 January 2019	10,609,868	1,007,198	842,828	163,114	12,623,008
Additions	-	10,297	48,268	15,155	73,720
Write off	(150,000)	-	(24,268)	(8,966)	(183,234)
At 31 December 2019	<u>10,459,868</u>	<u>1,017,495</u>	<u>866,828</u>	<u>169,303</u>	<u>12,513,494</u>
<u>Accumulated depreciation</u>					
At 1 January 2019	8,012,928	937,455	701,103	102,033	9,753,519
Depreciation charge for the financial year	624,015	35,770	96,805	13,348	769,938
Write off	(101,250)	-	(24,268)	(7,558)	(133,076)
At 31 December 2019	<u>8,535,693</u>	<u>973,225</u>	<u>773,640</u>	<u>107,823</u>	<u>10,390,381</u>
<u>Net book value</u>					
At 31 December 2019	<u>1,924,175</u>	<u>44,270</u>	<u>93,188</u>	<u>61,480</u>	<u>2,123,113</u>

CANCER RESEARCH MALAYSIA
(Incorporated in Malaysia as a company
limited by guarantee and not having a share capital)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2019 (CONTINUED)

6 PROPERTY, PLANT AND EQUIPMENT (CONTINUED)

Economic Entity and Foundation

	<u>Laboratory equipment</u> RM	<u>Renovations</u> RM	<u>Computers</u> RM	<u>Office equipment</u> RM	<u>Total</u> RM
<u>2018</u>					
<u>Cost</u>					
At 1 January 2018	10,608,121	1,007,198	784,411	172,169	12,571,899
Additions	14,247	-	87,380	795	102,422
Write off	(12,500)	-	(28,963)	(9,850)	(51,313)
At 31 December 2018	<u>10,609,868</u>	<u>1,007,198</u>	<u>842,828</u>	<u>163,114</u>	<u>12,623,008</u>
<u>Accumulated depreciation</u>					
At 1 January 2018	7,146,699	899,872	605,301	95,907	8,747,779
Depreciation charge for the financial year	872,584	37,583	124,765	15,102	1,050,034
Write off	(6,355)	-	(28,963)	(8,976)	(44,294)
At 31 December 2018	<u>8,012,928</u>	<u>937,455</u>	<u>701,103</u>	<u>102,033</u>	<u>9,753,519</u>
<u>Net book value</u>					
At 31 December 2018	<u><u>2,596,940</u></u>	<u><u>69,743</u></u>	<u><u>141,725</u></u>	<u><u>61,081</u></u>	<u><u>2,869,489</u></u>

CANCER RESEARCH MALAYSIA
(Incorporated in Malaysia as a company
limited by guarantee and not having a share capital)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2019 (CONTINUED)

7 RIGHT-OF-USE ASSET

	<u>2019</u> RM
<u>Building</u>	
<u>Cost</u>	
At 1 January, upon adoption of MFRS 16	219,473
At 31 December	<u>219,473</u>
<u>Accumulated depreciation</u>	
At 1 January, upon adoption of MFRS 16	-
Depreciation charge during the financial year	173,155
At 31 December	<u>173,155</u>
<u>Net book value</u>	
At 31 December	<u>46,318</u>
At 1 January, upon adoption of MFRS 16 (Note 14)	<u>219,473</u>

8 INVESTMENT IN JOINT VENTURE

	<u>Economic Entity</u>		<u>Foundation</u>	
	<u>2019</u> RM	<u>2018</u> RM	<u>2019</u> RM	<u>2018</u> RM
Unquoted shares in Malaysia, at cost	-	99,960	-	99,960
Add: Share of post-acquisition results and reserve	-	(94,438)	-	-
	<u>-</u>	<u>5,522</u>	<u>-</u>	<u>99,960</u>
Less: Accumulated impairment loss	-	(5,522)	-	(99,960)
	<u>-</u>	<u>-</u>	<u>-</u>	<u>-</u>

CANCER RESEARCH MALAYSIA

(Incorporated in Malaysia as a company
limited by guarantee and not having a share capital)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2019 (CONTINUED)**

8 INVESTMENT IN JOINT VENTURE (CONTINUED)

The joint venture listed below has share capital consisting solely of ordinary shares, which is held directly by the Foundation.

<u>Name of company</u>	<u>Place of incorporation</u>	<u>Principal activities</u>	<u>Foundation's effective interest</u>	
			<u>2019</u>	<u>2018</u>
			%	%
AseaCyte Sdn. Bhd.*	Malaysia	Rendering of services and products based in cell biology and cell culture technology	-	49.00

* Audited by a firm other than member firm of PricewaterhouseCoopers International Limited.

AseaCyte Sdn. Bhd. grants the Foundation 5 year royalty-free license for access to its cell biology and cell culture technology from 12 February 2010 to 11 February 2015.

The joint venture is a private company and there is no quoted market price available for its shares.

The joint venture company was no longer active since the financial year ended 31 December 2017. The Foundation has fully impaired the carrying value of the investment in the joint venture on the basis that the Foundation will be discontinuing with this joint venture arrangement and the recoverable amount is not expected to be significant.

On 7 October 2019, the process to strike-off the name of AseaCyte Sdn. Bhd. from the Register of the Companies Commission of Malaysia under Section 550 of the Companies Act 2016 (the Act") has been duly dissolved under the Act.

Set out below are the summarised financial information for AseaCyte Sdn. Bhd. which was accounted for using the equity method.

(a) Summarised statement of financial position

	<u>2018</u>
	RM
Net liabilities as at 1 January	(15,202)
	<u> </u>
Net assets/(liabilities) as at 31 December	-
	<u> </u>

CANCER RESEARCH MALAYSIA

(Incorporated in Malaysia as a company
limited by guarantee and not having a share capital)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2019 (CONTINUED)

8 INVESTMENT IN JOINT VENTURE (CONTINUED)

Set out below are the summarised financial information for AseaCyte Sdn. Bhd. which was accounted for using the equity method. (continued)

(b) Summarised statement of comprehensive income

	<u>2018</u> RM
Other operating income	23,937
Administrative expenses	(4,779)
Other operating expenses	(3,956)
Profit before tax	15,202
Income tax expense	-
Profit after tax	<u>15,202</u>

(c) Reconciliation of summarised financial information

The reconciliation between the summarised financial information and the carrying amount of the joint venture were as follows:

	<u>Economic Entity</u> <u>2018</u> RM
Opening net liabilities	(15,202)
Profit for the financial year	15,202
Closing net assets/(liabilities)	<u>-</u>

There are no commitments or contingent liabilities relating to the Foundation's interest in the joint venture.

CANCER RESEARCH MALAYSIA
(Incorporated in Malaysia as a company
limited by guarantee and not having a share capital)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2019 (CONTINUED)

9 RECEIVABLES

	<u>Economic Entity and Foundation</u>	
	<u>2019</u>	<u>2018</u>
	RM	RM
Donations receivable	1,315,497	851,307
Deposits	42,150	43,620
Interest receivable	121,506	98,892
Prepayment	167,165	13,511
Other receivables	-	54,961
GST input	428,448	428,448
	<u>2,074,766</u>	<u>1,490,739</u>

No loss allowance was recorded as at 31 December 2019 as the Trustees are of the view that the receivables are recoverable as at year end.

10 DEPOSITS, CASH AND BANK BALANCES

	<u>Economic Entity and Foundation</u>	
	<u>2019</u>	<u>2018</u>
	RM	RM
Fixed deposit with a licensed bank	11,230,000	12,475,707
Bank balances	596,224	827,659
Cash in hand	544	600
	<u>11,826,768</u>	<u>13,303,966</u>
Less: Fixed deposit with licensed bank more than 3 months	<u>(8,730,000)</u>	<u>(10,705,707)</u>
Cash and cash equivalents	<u>3,096,768</u>	<u>2,598,259</u>

The deposits with licensed bank carry fix interest rates ranging from 2.95% to 4.00% (2018: 3.10% to 3.90%) per annum as at the reporting date and have maturity periods ranging from one to twelve months (2018: one to six months).

CANCER RESEARCH MALAYSIA
(Incorporated in Malaysia as a company
limited by guarantee and not having a share capital)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2019 (CONTINUED)

11 LEASE LIABILITY

	<u>2019</u> RM
At 1 January (Note 14)	219,473
Interest accretion	5,247
Lease payment	(180,000)
At 31 December	<u>44,720</u>
	<u>31.12.2019</u> RM
Non-current	-
Current	44,720
	<u>44,720</u>
	<u>1.1.2019</u> RM
	174,753
	44,720
	<u>219,473</u>

Total cash outflow for leases of the Foundation are as follows:

	<u>2019</u> RM	<u>2018</u> RM
Rental expenses	-	321,021
Lease payment	180,000	-
Rental of other equipment (service contract)	49,427	-
Rental of low value assets	4,490	-
	<u>233,917</u>	<u>321,021</u>

12 PAYABLES

	<u>Economic Entity and Foundation</u>	
	<u>2019</u> RM	<u>2018</u> RM
Accruals	436,852	782,362
Other payables	75,726	201,578
GST output	48,249	48,249
	<u>560,827</u>	<u>1,032,189</u>

The fair value of payables approximates its carrying value, as the impact of discounting is not significant.

CANCER RESEARCH MALAYSIA

(Incorporated in Malaysia as a company
limited by guarantee and not having a share capital)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2019 (CONTINUED)**

13 DEFERRED INCOME

The Economic Entity and the Foundation obtained a government grant of RM3,500,000 in the financial year ended 31 December 2008 and were required to utilise the funds for certain projects and activities, including the acquisition of certain assets, as approved and prescribed under the terms of the grant. Government grant relating to the purchase of assets is credited to the income and expenditure statement on a straight line basis over the expected useful lives of the related assets. Government grant relating to costs is recognised in the income and expenditure statement over the periods to match the related costs for which the grants are intended to compensate.

	<u>Economic Entity and Foundation</u>	
	<u>2019</u>	<u>2018</u>
	RM	RM
Current	-	312,233
Non-current	-	-
At 31 December	-	312,233

The government grant was fully recognised during the current financial year.

14 EFFECTS OF CHANGE IN ACCOUNTING POLICY

The Foundation has applied MFRS 16 with the date of initial application of 1 January 2019 by applying the simplified retrospective transition method.

Under the simplified retrospective transition method, the 2018 comparative information was not restated and the cumulative effects of initial application of MFRS 16 where the Foundation is a lessee were recognised in the opening balance of statement of financial position as at 1 January 2019. The comparative information continued to be reported under the previous accounting policies governed under MFRS 117 "Leases" and IC Interpretation 4 "Determining whether an Arrangement Contains a Lease".

The Foundation has applied the practical expedient in applying MFRS 16 which at the date of initial application, no reassessments were made on whether existing contracts are, or contain, lease in accordance with MFRS 16. Accordingly, the Foundation has applied this Standard to contracts that were previously identified as leases applying MRS 117 and IC 4, while did not apply MFRS 16 to existing contracts that did not meet the definition of a lease under MFRS 117 and IC 4, although these contracts may meet the definition of lease under MFRS 16.

CANCER RESEARCH MALAYSIA

(Incorporated in Malaysia as a company
limited by guarantee and not having a share capital)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2019 (CONTINUED)

14 EFFECTS OF CHANGE IN ACCOUNTING POLICY (CONTINUED)

The Foundation as a lessee

(a) Leases classified as operating leases under MFRS 117

On adoption of MFRS 16, the Foundation recognised lease liabilities in relation to leases which had previously been classified as 'operating leases' under the principles of MFRS 117 Leases. These liabilities were measured at the present value of the remaining lease payments, discounted using the Foundation's incremental borrowing rate as of 1 January 2019 i.e. at 3.75% per annum.

Right-of-use assets were recognised and measured at the amount equal to the lease liability, adjusted by the amount of any prepaid or accrued lease payments relating to that lease recognised in the statement of financial position as at 31 December 2018.

In applying MFRS 16 for the first time, the Foundation has applied the following practical expedients permitted by the standard to leases previously classified as operating leases under MFRS 117:

- the use of a single discount rate to a portfolio of leases with reasonably similar characteristics;
- reliance on previous assessments on whether leases are onerous;
- the accounting for operating leases with a remaining lease term of less than 12 months as at 1 January 2019 as short-term leases;
- the exclusion of initial direct costs for the measurement of the ROU asset at the DIA; and
- the use of hindsight in determining the lease term where the contract contains options to extend or terminate the lease.

(b) Adjustments as at 1 January 2019

The table below shows the impact of changes to the statements of financial position of the Economic Entity and the Foundation resulting from the adoption of MFRS 16 as at 1 January 2019:

	As at 31 December 2018	Effects adoption of MFRS 16	As at 1 January 2019
<u>Non-current asset</u>			
Right-of-use asset	-	219,473	219,473
<u>Non-current liability</u>			
Lease liability	-	174,753	174,753
<u>Current liability</u>			
Lease liability	-	44,720	44,720

There is no impact on retained earnings on 1 January 2019.

CANCER RESEARCH MALAYSIA

(Incorporated in Malaysia as a company
limited by guarantee and not having a share capital)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2019 (CONTINUED)

14 **EFFECTS OF CHANGE IN ACCOUNTING POLICY (CONTINUED)**

(c) **Measurement of lease liabilities on 1 January 2019**

The reconciliation between the operating lease commitments disclosed applying MFRS 117 as at 31 December 2018 to the lease liabilities recognised as at 1 January 2019 is as follows:

	RM
Operating lease commitments as at 31 December 2018	225,000
Discounted using the Foundation's incremental borrowing rate of 3.75% at 1 January 2019	(5,527)
	<u>219,473</u>
Lease liability recognised as at 1 January 2019	<u>219,473</u>
Analysed as:	
Current	174,753
Non-current	44,720
	<u>219,473</u>

15 **AUTHORISATION FOR ISSUE OF FINANCIAL STATEMENTS**

The financial statements were authorised for issue by Trustees on 1 September 2020.

Registration No.

200001007481 (510087-M)

CANCER RESEARCH MALAYSIA

(Incorporated in Malaysia as a company
limited by guarantee and not having a share capital)

STATEMENT BY TRUSTEES PURSUANT TO SECTION 251(2) OF THE COMPANIES ACT 2016

We Toh Puan Dato' Seri Hajjah Dr Aishah Ong and Alan Hamzah Sendut, being two of the Trustees of Cancer Research Malaysia, do hereby state that, in the opinion of the Trustees, the financial statements set out on pages 4 to 31 are drawn up so as to give a true and fair view of the financial position of the Economic Entity and of the Foundation as at 31 December 2019 and financial performance of the Economic Entity and the Foundation for the financial year ended on that date in accordance with the Malaysian Financial Reporting Standards, International Financial Reporting Standards and the requirements of the Companies Act 2016 in Malaysia.

Signed on behalf of the Board of Trustees in accordance with the resolution of the Board of Trustees dated 1 September 2020.

TOH PUAN DATO' SERI HAJJAH
DR AISHAH ONG

TRUSTEE

ALAN HAMZAH SENDUT

TRUSTEE

STATUTORY DECLARATION PURSUANT TO SECTION 251(1) OF THE COMPANIES ACT 2016

I, Toh Puan Dato' Seri Hajjah Dr Aishah Ong, the Trustee primarily responsible for the financial management of Cancer Research Malaysia, do solemnly and sincerely declare that the financial statements set out on pages 4 to 31 are, in my opinion, correct and I make this solemn declaration conscientiously believing the same to be true, and by virtue of the provisions of the Statutory Declarations Act 1960.

TOH PUAN DATO' SERI HAJJAH
DR AISHAH ONG

Subscribed and solemnly declared by the above named Toh Puan Dato' Seri Hajjah Dr Aishah Ong at Selangor Darul Ehsan on 1 September 2020.

Before me,

COMMISSIONER FOR OATHS



TETUAN AISHAH KAMA & SABRI
WISMA REDLAND, NO. 3-1, 5-1 & 7-1,
JALAN USJ 1/1C, REGALIA BUSINESS CENTRE
47620 SUBANG JAYA, SELANGOR



**INDEPENDENT AUDITORS' REPORT
TO THE MEMBERS OF CANCER RESEARCH MALAYSIA**
(Incorporated in Malaysia as a company
Limited by guarantee and not having a share capital)
Registration No. 200001007481 (510087-M)

REPORT ON THE AUDIT OF THE FINANCIAL STATEMENTS

Our opinion

In our opinion, the financial statements of Cancer Research Malaysia ("the Economic Entity and the Foundation") give a true and fair view of the financial position of the Economic Entity and of the Foundation as at 31 December 2019, and of their financial performance and their cash flows for the financial year then ended in accordance with Malaysian Financial Reporting Standards, International Financial Reporting Standards and the requirements of the Companies Act 2016 in Malaysia.

What we have audited

We have audited the financial statements of the Economic Entity and of the Foundation, which comprise the statements of financial position as at 31 December 2019 of the Economic Entity and of the Foundation, and the income and expenditure statements, statements of changes in general funds and statements of cash flows of the Economic Entity and of the Foundation for the financial year then ended, and notes to the financial statements, including a summary of significant accounting policies, as set out on pages 4 to 31.

Basis for opinion

We conducted our audit in accordance with approved standards on auditing in Malaysia and International Standards on Auditing. Our responsibilities under those standards are further described in the "Auditors' responsibilities for the audit of the financial statements" section of our report.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Independence and other ethical responsibilities

We are independent of the Economic Entity and of the Foundation in accordance with the By-Laws (on Professional Ethics, Conduct and Practice) of the Malaysian Institute of Accountants ("By-Laws") and the International Ethics Standards Board for Accountants' International Code of Ethics for Professional Accountants (including International Independence Standards) ("IESBA Code"), and we have fulfilled our other ethical responsibilities in accordance with the By-Laws and the IESBA Code.



INDEPENDENT AUDITORS' REPORT
TO THE MEMBERS OF CANCER RESEARCH FOUNDATION (CONTINUED)
(Incorporated in Malaysia)
(Economic Entity and the Foundation No. 200001007481 (510087-M))

REPORT ON THE AUDIT OF THE FINANCIAL STATEMENTS (CONTINUED)

Information other than the financial statements and auditors' report thereon

The Trustees of the Foundation are responsible for the other information. The other information comprises the Trustee's Report but does not include the financial statements of the Economic Entity and of the Foundation and our auditors' report thereon.

Our opinion on the financial statements of the Economic Entity and of the Foundation does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements of the Economic Entity and of the Foundation, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements of the Economic Entity and of the Foundation or our knowledge obtained in the audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Responsibilities of the Trustees for the financial statements

The Trustees of the Foundation are responsible for the preparation of the financial statements of the Economic Entity and of the Foundation that give a true and fair view in accordance with Malaysian Financial Reporting Standards, International Financial Reporting Standards and the requirements of the Companies Act 2016 in Malaysia. The Trustees are also responsible for such internal control as the Trustees determine is necessary to enable the preparation of financial statements of the Economic Entity and of the Foundation that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements of the Economic Entity and of the Foundation, the Trustees are responsible for assessing the Economic Entity's and the Foundation's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Trustees either intend to liquidate the Economic Entity or the Foundation or to cease operations, or have no realistic alternative but to do so.

Auditors' responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements of the Economic Entity and of the Foundation as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with approved standards on auditing in Malaysia and International Standards on Auditing will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.



INDEPENDENT AUDITORS' REPORT
TO THE MEMBERS OF CANCER RESEARCH FOUNDATION (CONTINUED)
(Incorporated in Malaysia)
(Economic Entity and the Foundation No. 200001007481 (510087-M))

REPORT ON THE AUDIT OF THE FINANCIAL STATEMENTS (CONTINUED)

Auditors' responsibilities for the audit of the financial statements (continued)

As part of an audit in accordance with approved standards on auditing in Malaysia and International Standards on Auditing, we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- (a) Identify and assess the risks of material misstatement of the financial statements of the Economic Entity and of the Foundation, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- (b) Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Economic Entity's and of the Foundation's internal control.
- (c) Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Trustees.
- (d) Conclude on the appropriateness of the Trustees' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Economic Entity's or on the Foundation's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditors' report to the related disclosures in the financial statements of the Economic Entity and of the Foundation or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditors' report. However, future events or conditions may cause the Economic Entity and or the Foundation to cease to continue as a going concern.
- (e) Evaluate the overall presentation, structure and content of the financial statements of the Economic Entity and of the Foundation, including the disclosures, and whether the financial statements of the Economic Entity and of the Foundation represent the underlying transactions and events in a manner that achieves fair presentation.
- (f) Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the Economic Entity to express an opinion on the financial statements of the Economic Entity. We are responsible for the direction, supervision and performance of the Economic Entity audit. We remain solely responsible for our audit opinion.

We communicate with the Trustees regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.



INDEPENDENT AUDITORS' REPORT
TO THE MEMBERS OF CANCER RESEARCH MALAYSIA
(Incorporated in Malaysia as a company
Limited by guarantee and not having a share capital)
Registration No. 200001007481 (510087-M)

OTHER MATTERS

This report is made solely to the members of the Foundation, as a body, in accordance with Section 266 of the Companies Act 2016 in Malaysia and for no other purpose. We do not assume responsibility to any other person for the content of this report.


PRICEWATERHOUSECOOPERS FLT
LLP0014401-LCA & AF 1146
Chartered Accountants


MAHESH A/L RAMESH
03428/04/2021 J
Chartered Accountant

Kuala Lumpur
1 September 2020